Medicamen Biotech Limited has informed the Exchange about General Updates
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech received a cautionary email from the National Stock Exchange (NSE) on January 27, 2026, based on certain observations flagged by the Secretarial Auditor in the company's Secretarial Compliance Report for the financial year ended March 2025. NSE has advised the company to be careful in the future and avoid repeating such compliance lapses under the Listing Regulations. The company has stated that there is no impact on its financials, operations, or other activities. This is an advisory warning rather than a penalty or formal enforcement action.
No direct financial or operational impact on the company, but the cautionary letter signals minor compliance shortcomings that investors should track. Repeated lapses could attract stricter regulatory scrutiny in the future.